ReviewInfection & chemotherapy2021
Revised Korean Society of Infectious Diseases/National Evidence-based Healthcarea Collaborating Agency Guidelines on the Treatment of Patients with COVID-19.
Review in Infection & chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The effects of remdesivir on mortality and the requirement for mechanical ventilation in patients with COVID-19: a systematic review stratified by disease severity.The Korean journal of internal medicine · 2024Pooled it
- Pediatric COVID-19 in Korea: Lessons and Strategies for Future Disease-X Preparedness.Journal of Korean medical science · 2026Review
- Current status and clinical outcomes of pharmacotherapies according to SARS-CoV-2 mutations in patients with mild-to-moderate COVID-19: a retrospective single center study.BMC infectious diseases · 2024Article
- Antibiotic Prescription in Patients With Coronavirus Disease 2019: Analysis of National Health Insurance System Data in the Republic of Korea.Journal of Korean medical science · 2023Article
- Two Years of Experience and Methodology of Korean COVID-19 Living Clinical Practice Guideline Development.Journal of Korean medical science · 2023Article
- Multisystem Inflammatory Syndrome in Adults in an 80-Year-Old Korean Woman after COVID-19: A Case Report.Infection & chemotherapy · 2023Article
- COVID-19 Vaccination in Korea.Infection & chemotherapy · 2023Review
- An Open Label Randomized Controlled Trial of Ivermectin Plus Favipiravir-Based Standard of CareInfection & chemotherapy · 2023Article
- COVID-19 Outbreak in Daegu City, Korea and Response to COVID-19: How Have We Dealt and What Are the Lessons?Journal of Korean medical science · 2022Review
- How We Have Treated Severe to Critically Ill Patients With Coronavirus Disease 2019 in Korea.Journal of Korean medical science · 2022Review
- Treatment Options for Patients With Mild-to-Moderate Coronavirus Disease 2019 in Korea.Journal of Korean medical science · 2022Review
- Nirmatrelvir/Ritonavir Prescription Rate and Outcomes in Coronavirus Disease 2019: A Single Center Study.Infection & chemotherapy · 2022Article
- Impact of prior vaccination on clinical outcomes of patients with COVID-19.Emerging microbes & infections · 2022Article
- Risk factors and clinical impact of COVID-19-associated pulmonary aspergillosis: Multicenter retrospective cohort study.The Korean journal of internal medicine · 2022Article
- Development and Roll-Out of A Coronavirus Disease 2019 Clinical Pathway for Standardized Qualified Care in Public Hospitals in Korea.Infection & chemotherapy · 2022Article
- Effectiveness and Safety of Regdanvimab in Patients With Mild-To-Moderate COVID-19: A Retrospective Cohort Study.Journal of Korean medical science · 2022Article
- A Direct Rapid Phenotypic Antimicrobial Susceptibility Test Enables Early Selection of Optimal Antibiotics to Treat Bacteremia in COVID-19 Patients.Infection & chemotherapy · 2021Article
- Korean Society of Infectious Diseases/National Evidence-based Healthcare Collaborating Agency Recommendations for Anti-SARS-CoV-2 Monoclonal Antibody Treatment of Patients with COVID-19.Infection & chemotherapy · 2021Article
- Collaborative Response to COVID-19 Pandemic, and Development of Treatment Guidelines.Infection & chemotherapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
Despite the global effort to mitigate the spread, coronavirus disease 2019 (COVID-19) has become a pandemic that took more than 2 million lives. There are numerous ongoing clinical studies aiming to find treatment options and many are being published daily. Some effective treatment options, albeit of variable efficacy, have been discovered. Therefore, it is necessary to develop an evidence-based methodology, to continuously check for new evidence, and to update recommendations accordingly. Here we provide guidelines on pharmaceutical treatment for COVID-19 based on the latest evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.